1,179
Views
1
CrossRef citations to date
0
Altmetric
Commentary

Opioid use disorder deaths and the effects of medication therapy

&
Pages 227-229 | Received 04 Feb 2019, Accepted 05 Feb 2019, Published online: 08 Mar 2019

References

  • Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths — United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2019;67:1419–27. doi:10.15585/mmwr.mm675152e1.
  • Robinson SM, Adinoff B. The mixed message behind “Medication-Assisted Treatment” for substance use disorder. Am J Drug Alcohol Abuse. 2018;44(2):147–50. doi:10.1080/00952990.2017.1362419.
  • Sofuoglu M, DeVito EE, Carroll KM. Pharmacological and behavioral treatment of opioid use disorder. Psyc Res Clin Pract. 2018 Dec 5. https://doi.org/10.1176/appi.prcp.20180006
  • Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333.
  • Degenhardt L, Larney S, Kimber J, Farrell M, Hall W. Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug Alcohol Rev. 2015 Jan; 34(1): 90–96. doi:10.1111/dar.12205.
  • Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, et al. Randomized trial of long-acting sustained-release naltrexone implant vs. oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012 Sep; 69(9): 973–81. doi:10.1001/archgenpsychiatry.2012.1a.
  • Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018 Jul; 113(7): 1188–209. doi:10.1111/add.14180.
  • Kelty E, Joyce D, Hulse G. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine. Am J Drug Alcohol Abuse. 2019.
  • Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27;391(10118):309–18. doi:10.1016/S0140-6736(17)32812-X.
  • Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017 Dec 1;74(12):1197–205. doi:10.1001/jamapsychiatry.2017.3206.
  • Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Woody GE, Kosten TR. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018 Apr; 27(3): 177–87. doi:10.1111/ajad.12711.
  • Braden JB, Edlund MJ, Sullivan MD. Suicide deaths with opioid poisoning in the United States: 1999-2014. Am J Public Health. 2017 Mar; 107(3): 421–26. doi:10.2105/AJPH.2016.303591.
  • Ilgen MA, Bohnert AS, Ganoczy D, Bair MJ, McCarthy JF, Blow FC. Opioid dose and risk of suicide. Pain. 2016 May; 157(5): 1079–84. doi:10.1097/j.pain.0000000000000484.
  • Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. N Engl J Med. 2019 Jan 3;380(1):71–79. doi:10.1056/NEJMra1802148.
  • VanHouten JP, Rudd RA, Ballesteros MF, Mack KA. Drug overdose deaths among women aged 30–64 years — united States, 1999–2017. MMWR Morb Mortal Wkly Rep. 2019;68:1–5. doi:10.15585/mmwr.mm6801a1.
  • Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2010;106:32–51.
  • Wu LT, Woody GE, Yang C, Mannelli P, Blazer DG. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the national epidemiologic survey on alcohol and related conditions. Subst Abuse Rehabil. 2011;2011(2):77–88. doi:10.2147/SAR.S18969.
  • Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017 Apr 26;357:j1550. doi:10.1136/bmj.j2024.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.